(2S)-6-Chloro-imidazo[2,1-b]thiazole-5-carboxylic acid [1-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-azetidin-2-ylmethyl]-amide | 1007874-61-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (2S)-6-Chloro-imidazo[2,1-b]thiazole-5-carboxylic acid [1-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-azetidin-2-ylmethyl]-amide
• 英文别名: (2RS)-6-chloroimidazo[2,1-b]thiazole-5-carboxylic acid [1-(2-methyl-5-m-tolylthiazole-4-carbonyl)azetidin-2-ylmethyl]amide；6-chloro-N-[[1-[2-methyl-5-(3-methylphenyl)-1,3-thiazole-4-carbonyl]azetidin-2-yl]methyl]imidazo[2,1-b][1,3]thiazole-5-carboxamide
• CAS: 1007874-61-4
• 化学式: C₂₂H₂₀ClN₅O₂S₂
• 分子量: 486.018
• InChiKey: NPZSQOCJCVLKOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  136
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Methods and pharmaceutical compositions for the treatment of cancer
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

  公开号：US10894042B2

  公开（公告）日：2021-01-19

  The present invention relates to methods and pharmaceutical compositions for the treatment of cancer. More particularly, the present invention relates to a method of treating cancer in subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R antagonist.

  本发明涉及治疗癌症的方法和药物组合物。更具体地说，本发明涉及一种治疗有需要的受试者癌症的方法，该方法包括向受试者施用治疗有效量的至少一种 OX1R 拮抗剂。
• AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP2069332B1

  公开（公告）日：2011-03-02
• METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATORY
  申请人：INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCJAE MÉDICALE

  公开号：US20190151304A1

  公开（公告）日：2019-05-23

  The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases. The inventors showed that orexin receptor antagonists have anti-inflammatory properties. Indeed, these compounds are antagonist for OX1R-mediated calcium mobilization but a full agonist for OX1R-mediated mitochondrial apoptosis, which is the mechanism involved in the improvement of resolution of inflammation observed in the models of colitis, multiple sclerosis and pancreatitis. In particular, the present invention relates to a method of treating an autoimmune inflammatory disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of at least one OX1R antagonist.
• US7994336B2
  申请人：——

  公开号：US7994336B2

  公开（公告）日：2011-08-09